WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research Dr Lana Kandalaft from the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.[audio:https://www.audiomedica.com/podcasting/oncology/130407LanaKandalaftPODCASTLoRes.mp3]
You may also like...
Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY 30 Mar, 2018 Lung Cancer Radiation Therapy Increases Heart Disease Mortality 24 Aug, 2016 PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018 Targeting Bone Microenvironment in Breast Cancer 27 Mar, 2015
- Previous story Blood test for free tumour DNA could guide breast cancer therapy
- Next story Treating HER 2 positive metastatic breast cancer without chemotherapy?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014